The US Food and Drug Administration has informed Ireland-incorporated specialty pharma firm Mallinckrodt (NYSE: MNK) that it is deferring action (pending a site inspection) on the Stratatech Biologics License Application (BLA) for StrataGraft, an investigational allogeneic cellularized scaffold product in development for the treatment of adult patients with deep partial-thickness burns.
This is due to COVID-19-related travel restrictions, which are delaying a required manufacturing site inspection, said Mallinckrodt, which acquired rights to the product with its acquisition of Stratatech Corp, a privately-held Wisconsin-based regenerative medicine company, in 2016.
At that time, Mallinckrodt said that, if approved, StrataGraft could be the first biological "off-the-shelf" skin substitute product for treatment of severe burns. Mallinckrodt estimated the market size at $300 million based off the treatment of 10,000 patients annually for severe burns in the USA.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze